RxDoctor Payments DataLook up a doctor →

Laura Howe, MD

Allergy & Immunology · Traverse City, MINPI 1407053275

Payments from drug & device makers

$13,404in general payments, 2019–2025

Across 673 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Sanofi$1K
  • Amgen$844
  • CSL Behring$748
  • Regeneron Healthcare Solutions, Inc.$680
  • plus $5K from 36 others

What the payments were for

  • Consulting fees$410%
  • Food & beverage$13,22899%
  • Education$771%
  • Other$580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,404 in reported general payments places this provider in the 75th percentile of 119 allergy & immunology providers in Michigan.

See all allergy & immunology providers in Michigan

Medicare billing

Part B allowed, 2024
$76,296
Medicare patients
122
Services billed
4,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab44$163,410
NucalaMepolizumab25$91,013
Dupixent PenDupilumab21$77,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,500
Breo ElliptaFluticasone/Vilanterol19$7,627
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$5,909
Epinephrine23$5,390
Ipratropium Bromide164$4,706
Arnuity ElliptaFluticasone Furoate18$4,199
Albuterol Sulfate HfaAlbuterol Sulfate38$1,282
Fluticasone Propionate73$1,204
Azelastine Hcl33$762
Montelukast Sodium20$303
Prednisone41$163
Famotidine26$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta$2,072$113,34077 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 119 allergy & immunology providers in Michigan.

Other allergy & immunology in Traverse City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →